| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/16/2002 | US6420342 Ribose, folic acid, orotic acid |
| 07/16/2002 | US6420337 Protein isolated from egg whites and yolks of hyperimmunized animals; amino acid sequence seq id no:1 and 6; upregulation of tumor necrosis factor and interleukins-6 and -1beta; downregulation of transforming growth factor-beta |
| 07/16/2002 | US6420335 Cancer therapy; angiostatin or endostatin to sensitize tumor endothelial cells to ionizing radiation |
| 07/16/2002 | US6420172 Method for inducing tumor immunity |
| 07/16/2002 | US6420171 Composite material for use in the isolation of aggregations of cells associate with preferential blood disorders |
| 07/16/2002 | US6420155 Polypeptide for use in the treatment of cancer and atherosclerosis |
| 07/16/2002 | US6420126 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 07/16/2002 | US6420118 Monitoring activity of mutant tumor suppressor protein; obtain sample containing mutant peptide, incubate with wild type cell, monitor tumor suppression activity of cells |
| 07/16/2002 | CA2286296C Inhibitors for urokinase receptor |
| 07/16/2002 | CA2253663C Hgh-rh(1-29)nh2 analogues having antagonistic activity |
| 07/16/2002 | CA2249418C Anticancer drug |
| 07/16/2002 | CA2240846C Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| 07/16/2002 | CA2214097C Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| 07/16/2002 | CA2171738C Parenteral busulfan for treatment of malignant disease |
| 07/16/2002 | CA2095926C Anti-human milk fat globule humanised antibodies |
| 07/11/2002 | WO2002054066A2 Non-apoptotic forms of cell death and methods of modulation |
| 07/11/2002 | WO2002054064A2 Method for screening for progesterone receptor isoform-specific ligands |
| 07/11/2002 | WO2002053775A2 Identification of genetic determinants of polymorphic cyp3a5 expression |
| 07/11/2002 | WO2002053770A2 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests |
| 07/11/2002 | WO2002053742A2 Proteins and nucleic acids encoding same |
| 07/11/2002 | WO2002053740A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/11/2002 | WO2002053737A1 Nf-kb activating gene |
| 07/11/2002 | WO2002053717A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/11/2002 | WO2002053711A2 Use of transcription factor yb-1 in adenoviral systems |
| 07/11/2002 | WO2002053700A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 07/11/2002 | WO2002053596A2 Antibodies to insulin-like growth factor i receptor |
| 07/11/2002 | WO2002053581A2 Spliceosome mediated rna trans-splicing |
| 07/11/2002 | WO2002053557A1 Novel sulfamides and their use as endothelin receptor antagonists |
| 07/11/2002 | WO2002053534A1 Vla-4 inhibitors |
| 07/11/2002 | WO2002053528A1 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines |
| 07/11/2002 | WO2002053523A1 Tropolone derivative |
| 07/11/2002 | WO2002053522A2 Novel estrogen receptor ligands and methods i |
| 07/11/2002 | WO2002053519A2 Hydrophobic polyamine analogs and methods for their use |
| 07/11/2002 | WO2002053185A2 Anti-inflammatory use of polycationic compounds |
| 07/11/2002 | WO2002053184A2 Uses for polycationic compounds as vaccine adjuvants |
| 07/11/2002 | WO2002053170A2 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological diseases associated with fo |
| 07/11/2002 | WO2002053165A1 Natural anti-angiogenic composition, method of preparation thereof and its application |
| 07/11/2002 | WO2002053152A1 Composition containing flavonoids for treatment brain disorders |
| 07/11/2002 | WO2002053149A2 Medicament containing a polyamine as an active substance |
| 07/11/2002 | WO2002053142A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 07/11/2002 | WO2002053141A2 Inhibition of angiogenesis by nucleic acids |
| 07/11/2002 | WO2002053138A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| 07/11/2002 | WO2002053130A2 Sustained release drug delivery devices with coated drug cores |
| 07/11/2002 | WO2002053110A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002052956A1 Antitumor food or beverage |
| 07/11/2002 | WO2002052936A1 Preserving agents for freeze-dried cells |
| 07/11/2002 | WO2002040507A3 Novel compounds for uses in radioimmunoscintigraphy and/or radioimmunotherapy of cancers |
| 07/11/2002 | WO2002034119A3 Vaccine immunotherapy for immune suppressed patients |
| 07/11/2002 | WO2002030970A3 Human histone deacetylase gene |
| 07/11/2002 | WO2002028480A3 Methods of therapy for b-cell malignancies |
| 07/11/2002 | WO2002028349A3 Method of treating cancer using dithiocarbamate derivatives |
| 07/11/2002 | WO2002026716A3 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002017914A8 Fused pyrrolocarbazoles against inflammation |
| 07/11/2002 | WO2002014511A3 Regulation of human p2y1-like g protein-coupled receptor |
| 07/11/2002 | WO2002011666A3 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 07/11/2002 | WO2002010199A3 C3b/c4b complement receptor-like molecules and uses thereof |
| 07/11/2002 | WO2002008456A8 Method for identifying metastatic tumor cells |
| 07/11/2002 | WO2002008286A3 Zinc finger domain recognition code and uses thereof |
| 07/11/2002 | WO2001096311A3 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 07/11/2002 | WO2001083781A3 14094, a novel human trypsin family member and uses thereof |
| 07/11/2002 | WO2001080896A3 Flavopiridol drug combinations and methods with reduced side effects |
| 07/11/2002 | WO2001078756A3 Agent for postoperative use after the removal of bone tumours |
| 07/11/2002 | WO2001077377A3 Diagnosis of diseases associated with dna replication by assessing dna methylation |
| 07/11/2002 | WO2001076556A3 Lipid-based drug delivery systems against parasitic infections |
| 07/11/2002 | WO2001068145A3 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001043540A3 Methods for producing transgenic animals |
| 07/11/2002 | WO2001039763A3 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001031580A3 Methods and devices for identifying patterns in biological systems |
| 07/11/2002 | WO2001025438A3 Ifn-alpha homologues |
| 07/11/2002 | WO2001025273A3 Compositions and methods for wt1 specific immunotherapy |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2001017563A3 Integrin-mediated drug targeting |
| 07/11/2002 | WO2001017517A3 Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer |
| 07/11/2002 | WO2001015729A9 Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses |
| 07/11/2002 | WO2001012809A3 Heterodimeric vegf variants used for inhibiting angiogenesis |
| 07/11/2002 | WO2000075144A9 Peroxynitrite decomposition catalysts and methods of use thereof |
| 07/11/2002 | WO2000073321A9 Human tumor necrosis factor receptor tr10 |
| 07/11/2002 | WO2000073263A9 Cytofectin dimers and methods of use thereof |
| 07/11/2002 | WO2000066179A9 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 07/11/2002 | WO2000063438A3 Method of classifying a thyroid carcinoma using differential gene expression |
| 07/11/2002 | WO2000062067A9 Novel transduction molecules and methods for using same |
| 07/11/2002 | WO2000049937A9 Trpm-2 antisense therapy |
| 07/11/2002 | US20020091279 15R-5,6,15-trihydroxy-7,9,13-trans- 11-cis-eicosatetraenoic oracid,15R-5,14,15-trihydroxy-6,10,12-trans-8-cis-eicosatetraenoic acid, or 15-hydroxyeicosatetraenoic acid; anticarcinogenic agents |
| 07/11/2002 | US20020091273 Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines |
| 07/11/2002 | US20020091269 Synthesis of epothilones and related analogs |
| 07/11/2002 | US20020091263 Biaryl substituted purine derivatives as potent antiproliferative agents |
| 07/11/2002 | US20020091261 Phthalazines with angiogenesis inhibiting activity |
| 07/11/2002 | US20020091251 Preparing preefrentially linked chemical intermediates; obtain hyaluronic acid, incubate with glutaraldehyde, recover reaction product |
| 07/11/2002 | US20020091249 Human tumor suppressor polypeptides |
| 07/11/2002 | US20020091247 Polycyclic aromatic hydrocarbon induced molecules |
| 07/11/2002 | US20020091246 Dendritic cell co-stimulatory molecules |
| 07/11/2002 | US20020091244 Nucleotide sequences for use in diagnosis and treatment of cancer and immunological disorders |
| 07/11/2002 | US20020091157 Cyclic GMP (cGMP)-specific phosphodiesterase (PDE) inhibitor (e.g., exisulind) to reduce the side effects or increase the efficacy of treatment with an antineoplastic platinum coordination complex like cisplatin or carboplatin. |
| 07/11/2002 | US20020091145 Behavior chemotherapy |
| 07/11/2002 | US20020091143 Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 |